Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant paclitaxel + carboplatin followed by dose-dense epirubicin + cyclophosphamide in stage II–III triple negative breast cancer
2014-003723-21Phase 2Completed
- Sponsor
- Belgian Society of Medical Oncology
- Start
- Feb 2015
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel, carboplatin, epirubicin and cyclophosphamide in triple-negative breast cancer (TNBC), sponsored by Belgian Society of Medical Oncology. Primary endpoint: Pathological complete response in breast and axilla. Started Feb 2015; status: completed.
02
Drugs
paclitaxelcarboplatinepirubicincyclophosphamide
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2014-003723-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003723-21.